Understanding Medical Decision-making in Prostate Cancer Care

Thera, Rachel; Carr, Tracey; Groot, Gary; Baba, Nicole; Jana, Kunal

doi:10.1177/1557988318780851

Cited by 16 publications

(26 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oncology nurses can provide vital assistance to patients who may be incapable of processing and retaining all information conveyed to them during an initial encounter and who may prefer to maintain an active role in their treatment journey 21,22 . Another important role of nurse specialists throughout the therapeutic course is to provide patients with reliable, factual information on what to expect from their prescribed treatment regimen, including TEAEs and life expectancy.…”

Section: Tailoring Treatment To Patientsmentioning

confidence: 99%

“…Another important role of nurse specialists throughout the therapeutic course is to provide patients with reliable, factual information on what to expect from their prescribed treatment regimen, including TEAEs and life expectancy. Patients should be encouraged to ask questions if any aspects of their diagnosis, case management or prognosis remain unclear to them after initial meetings with their HCP 22,28 …”

Section: Tailoring Treatment To Patientsmentioning

confidence: 99%

“…These AEs can be a concern for patients with PC as they may impact QoL and functional capacity, and exacerbate comorbid symptoms 33,34 . It is important that nurses communicate clearly with their patients on which AEs may affect them based on their therapeutic regimen and current health status 22 and distinguish these from less likely events. Patients should be encouraged to contact their nurses immediately if they experience TEAEs, as nurses can offer valuable insight and advice on first‐line management techniques and support patients to seek further advice as needed, depending on the severity of the event 35 …”

Section: Tailoring Treatment To Patientsmentioning

confidence: 99%

“…Oncology nurses play a pivotal role in the management of patients with PC by educating them on disease state, risk and likelihood of progression, respective therapeutic options and TEAEs along their individualized treatment path. Nurse specialists may participate in treatment strategy, for example, collaborating with oncologists and urologists 21,22 on the possible benefits of a temporary dose reduction or interruption, or choosing the most appropriate treatment option for individual patients depending on their comorbidities and associated comedications. Shared decision‐making strategies include patient education and referrals (individually or in groups) to resources for self‐care 22 .…”

Section: Role Of the Nurse Specialist In Managing Adverse Drug Eventsmentioning

confidence: 99%

“…Nurses often assume the frontline responsibility for identifying and subsequently managing TEAEs 21 . Nurses also can offer emotional support to patients and their families and improve coordination of services and interventions between members of the wider multidisciplinary team 21,22 …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

New treatments for patients with non‐metastatic castration‐resistant prostate cancer: A nursing perspective

Olivier

Floyd

Smith

et al. 2021

Int J of Uro Nursing

View full text Add to dashboard Cite

Globally, prostate cancer (PC) is a leading cause of death in men. Although androgen deprivation therapy (ADT) is the cornerstone of treatment for the disease, most patients eventually develop castration‐resistant PC (CRPC). Patients with non‐metastatic (nm) CRPC, the earliest clinical manifestation of castration resistance, are at risk of progressing to metastatic CRPC, which is associated with reduced life expectancy and poor quality of life. The nmCRPC treatment landscape has recently been transformed by the approval of three next‐generation oral androgen receptor (AR) inhibitors: apalutamide, enzalutamide and darolutamide. This review addresses available new treatment options for nmCRPC that target the AR, considering the effects of adverse event (AE) profiles and drug‐drug interactions (DDIs) when tailoring patient‐centric treatment to individual need, and discussing management strategies and nursing interventions for patients who experience drug‐related AEs. While no head‐to‐head comparisons of apalutamide, enzalutamide and darolutamide have been conducted to date, all three drugs have demonstrated comparable efficacy and maintained quality of life in phase III clinical trials, with differing AE profiles. The three treatments also demonstrate different potential for DDIs with other common medications that may be taken simultaneously. With the availability of new AR‐targeted options for nmCRPC, oncology nurses play a crucial role in the decision‐making process, educating and supporting patients on managing their PC, and ensuring that they receive the most appropriate treatment. As patients with nmCRPC are largely asymptomatic from their disease (with the exception of urinary/erectile symptoms), maintaining quality of life becomes a major objective when prescribing pharmacotherapy. Therefore, weighing treatment efficacy against the respective drug safety profile and examining the potential for adverse drug interactions with concomitant medications are important clinical considerations. Oncology nurses educate patients on potential treatment‐emergent AEs and their management and serve as advocates to ensure that patients receive optimal care based on their individual therapeutic requirements. They also provide information on available auxiliary services for patients and caregivers. This article provides an overview for the oncology nurse of the efficacy, safety, quality of life and DDI potential of these new AR‐targeted therapies in the nmCRPC setting, highlighting considerations for tailoring patient‐centric treatment to individual need. The importance of the oncology nurse in managing adverse drug reactions associated with ADT and AR inhibitors is highlighted and recommendations provided.

show abstract

Section: Tailoring Treatment To Patientsmentioning

confidence: 99%

Section: Tailoring Treatment To Patientsmentioning

confidence: 99%

Section: Tailoring Treatment To Patientsmentioning

confidence: 99%

Section: Role Of the Nurse Specialist In Managing Adverse Drug Eventsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

New treatments for patients with non‐metastatic castration‐resistant prostate cancer: A nursing perspective

Olivier

Floyd

Smith

et al. 2021

Int J of Uro Nursing

View full text Add to dashboard Cite

show abstract

Quality of life assessment among ethnically diverse Black prostate cancer survivors: a constructivist grounded theory approach

Ogunsanya,

Kaninjing,

Ellis

et al. 2024

J Cancer Surviv

View full text Add to dashboard Cite

Purpose: Prostate cancer (CaP) is the most common cancer in Black men (BM), and the number of Black CaP survivors is rapidly increasing. Although Black immigrants are among the fastest-growing and most heterogeneous ethnic groups in the US, limited data exist regarding their CaP experiences. Therefore, this study aimed to explore and model the experiences of ethnically diverse Black men with CaP.Methods: In-depth interviews were conducted with 34 participants: Native-born BM (NBBM) (n=17), African-born BM (ABBM) (n=11), and Caribbean-born BM (CBBM) (n=6) CaP survivors recruited through QR-code embedded yers posted in Black businesses, clinics, social media platforms, and existing research networks within the US. Guided by Charmaz's constructivist grounded theory methodology, the interviews were analyzed using constant comparison following key stages of initial, focused, and theoretical coding using Atlas.ti v23.Results: Participants were thirty-four men aged 49-84 years (mean±SD, 66±8). Most were married (77%), likely to be diagnosed at Stage I (35%), and treated with radiotherapy (56%). Our study ndings explored the complex trajectory of Black prostate cancer (CaP) survivors, unveiling a comprehensive model termed "Journeying through Unfamiliar Terrain." Comprising three phases and 11 sub-phases, this model uniquely captures the pre-diagnosis awareness and post-treatment adaptation among survivors. Conclusion: The resulting theoretical model delineates the entire CaP survivorship process among BM, providing contextual and conceptual understanding for developing interventions and enhancing patientcentered care for ethnically diverse CaP survivors, pivotal in bridging the gaps in survivorship research and healthcare practices.

show abstract

Decision-making support among racial and ethnic minorities diagnosed with breast or prostate cancer: A systematic review of the literature

DeRosa

Grell

Razon

et al. 2022

Patient Education and Counseling

View full text Add to dashboard Cite

Understanding Medical Decision-making in Prostate Cancer Care

Cited by 16 publications

References 26 publications

New treatments for patients with non‐metastatic castration‐resistant prostate cancer: A nursing perspective

New treatments for patients with non‐metastatic castration‐resistant prostate cancer: A nursing perspective

Quality of life assessment among ethnically diverse Black prostate cancer survivors: a constructivist grounded theory approach

Decision-making support among racial and ethnic minorities diagnosed with breast or prostate cancer: A systematic review of the literature

Contact Info

Product

Resources

About